<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01857843</url>
  </required_header>
  <id_info>
    <org_study_id>1-2009-0032</org_study_id>
    <nct_id>NCT01857843</nct_id>
  </id_info>
  <brief_title>Early Effects of Intensive Lipid Lowering Treatment With Ezetimibe/ Simvastatin (Vytorin®) Assessed by Virtual Histology-Intravascular Ultrasound (VH-IVUS) and Optical Coherence Tomography (OCT) on Plaque Characteristics in Patients With Acute Coronary Syndrome</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: To evaluate the early effects of intensive lipid lowering treatments with
      ezetimibe/simvastatin (Vytorin®) for each component of coronary plaques.

      Study Design

        -  Prospective, randomized, single-center study of each 80 subjects enrolled

        -  Subjects with acute coronary syndrome who meet all inclusion and exclusion criteria will
           be enrolled.

        -  Eligible subjects will be randomized 1:1 to A) Ezetimibe/Simvastatin (n=80) vs. B)
           Pravastatin (n=80), and each group of patients will be randomized further in a ratio of
           1:1 to a) ZES (n=40) vs. b) EES (n=40), according to the type of stent used.

        -  All subjects will undergo VH-IVUS at initial procedure.

        -  Follow-up VH-IVUS will be performed at 3 months after index procedure. OCT at initial
           procedure and 3-months will be performed in available cases.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quantitative change in fibrofatty component of plaque measured by VH-IVUS</measure>
    <time_frame>baseline and 3 months</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>ZES group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>EES group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vytorin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mevalotin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Zotalolimus Eluting Stent</intervention_name>
    <description>Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.
Patients with native coronary arteries who fulfill all enrollment criteria for OCT study will be randomized to receive either ZES (Endeavor®-Sprint or Resolute-integrity) or EES (Xience®) in a ratio of 1:1.</description>
    <arm_group_label>ZES group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Everolimus eluting stent</intervention_name>
    <description>Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.
Patients with native coronary arteries who fulfill all enrollment criteria for OCT study will be randomized to receive either ZES (Endeavor®-Sprint or resolute-integrity) or EES (Xience®) in a ratio of 1:1.</description>
    <arm_group_label>EES group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe 10mg &amp; Simvastatin 40mg</intervention_name>
    <description>Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.
Patients will be randomized in a ratio of 1:1 according to the two different types of lipid lowering treatment.
Ezetimibe 10mg/Simvastatin 40mg (Vytorin®, MSD)
Pravastatin 20mg (mevalotin®, BMS)</description>
    <arm_group_label>Vytorin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pravastatin 20mg</intervention_name>
    <description>Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.
Patients will be randomized in a ratio of 1:1 according to the two different types of lipid lowering treatment.
Ezetimibe 10mg/Simvastatin 40mg (Vytorin®, MSD)
Pravastatin 20mg (mevalotin®, BMS)</description>
    <arm_group_label>Mevalotin group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        General inclusion criteria

          1. Acute coronary syndrome including unstable angina, acute non-ST elevation myocardial
             infarction and acute ST elevation myocardial infarction

          2. Age of 20 years or older

          3. Patients with signed informed consent

        Angiographic inclusion criteria

          1. De novo lesion without significant plaque (angiographic lumen diameter stenosis &lt; 50%)

          2. Reference vessel diameter ?&gt; 3.0 mm by operator assessment

          3. Segment length of 10-20 mm

          4. Distance from the PCI site &gt; 5.0mm (either proximal or distal)

          5. Available for serial high quality IVUS studies of the entire segment.

        Exclusion Criteria:

          1. Failed PCI

          2. Recommended coronary artery bypass grafting (CABG)

          3. Cardiogenic Shock

          4. Administration of lipid lowering agents before enrollment

          5. Significant hepatic dysfunction (3 times normal reference values)

          6. Significant renal dysfunction (Serum creatinine &gt; 2.0 mg/dl)

          7. Significant leukopenia, thrombocytopenia, anemia, or known bleeding diathesis

          8. Pregnant women or women with potential childbearing

          9. Saphenous vein graft
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2013</study_first_submitted>
  <study_first_submitted_qc>May 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2013</study_first_posted>
  <last_update_submitted>February 4, 2014</last_update_submitted>
  <last_update_submitted_qc>February 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
    <mesh_term>Pravastatin</mesh_term>
    <mesh_term>Ezetimibe, Simvastatin Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

